Data From Eli Lilly’s COV-BARRIER Trial Shows Baricitinib Reduced Deaths In Hospitalised COVID-19 Patients By 38%
January 27, 2021
BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target
November 20, 2020
FDA Grants Emergency Use Authorisation For Baricitinib In Hospitalised COVID-19 Patients Nine Months After Initial Hypothesis Was Published By BenevolentAI
April 10, 2020
Potential Treatment For COVID-19 Identified By BenevolentAI Enters Randomised Clinical Trial
April 29, 2019
AstraZeneca Starts Artificial Intelligence Collaboration To Accelerate Drug Discovery